I love some vax companies & plays, HOWEVER I'm noticing a conversational shift from vaccines to therapeutics. Things to consider heading into fall:
- Vaccines only have to be effective in 50% of patients to be approved
- Lets say 70% get vaccinated (HIGH estimate IMO)...

... with 70% vaccination rate + 50% efficacy, that delivers some (variable) immunity to 35% of the population.
- the other 65% are still vulnerable to contracting COVID-19. *Not counting the ~18M confirmed infections (rough estimate) because it is less than 1% global population

So, at least 65% still need a treatment plan. That's where therapeutics come in. So far, many have produced lackluster results & are EXPENSIVE and hard to obtain. There are still huge investing opportunities in therapeutics, many currently in trials. $RLFTF = top of my list.

For vax plays, front-runners seem to have topped out. Sticking with vaccines that have a clear differentiator from or advantage over those in late phase trials (intranasal, oral pill, attenuated live vaxs, mucosal immunity)